Search results
Results from the WOW.Com Content Network
The concept of blocking PD-1 and PD-L1 for the treatment of cancer was first published in 2001. [6] Pharmaceutical companies began attempting to develop drugs to block these molecules, and the first clinical trial was launched in 2006, evaluating nivolumab.
Curex is an American telehealth company specializing in immunology, specifically the diagnosis and treatment of allergies, including the prescription and delivery of allergy immunotherapy. [1] The company was founded by Gene Kakaulin and Charles Jacoby in 2020 [ 2 ] and is headquartered in New York City. [ 3 ]
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology ( immuno-oncology ) and a growing subspecialty of oncology .
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .
In September 2014, a new cancer immunotherapy for melanoma patients called Keytruda became the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States. Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at Moffitt, was one of the lead investigators of the clinical trial ...
The U.S. health regulator's approval extends Keytruda's use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients. The U.S. drugmaker is ...
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein.
The therapy, branded as Ryoncil, is the first mesenchymal stromal cell therapy approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard ...